ArticleBreast (Edinburgh, Scotland)2026
Phase I study of stereotactic ablative radiotherapy (SABR) in inoperable breast cancer.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA significant percentage of elderly patients with early-stage breast cancer are not surgical candidates or refuse surgery, and exclusive hormone therapy offers poor local control. SABR, by delivering biologically ablative doses in a few fractions, could be a non-invasive and effective alternative. This phase I clinical trial's primary objective was to determine the safety, tolerability, and maximum tolerated dose (MTD) of SABR as a definitive treatment in this population. MATERIAL AND
methodsA single-center, single-arm, phase I study was designed. Eligible patients were ≥70 years old with unifocal, T1-2N0 M0-1 breast cancer, considered inoperable or who refused surgery. A Fibonacci (3 + 3) dose-escalation design was used to deliver SABR to the primary tumor in 5 fractions. Dose levels were 36 Gy (Level 1), 38 Gy (Level 2), and 40 Gy (Level 3). The primary endpoint was dose-limiting adverse effects, defined as any ≥ Grade 3 events (per RTOG/Harris scales) within the first 6 months. Secondary endpoints included local control (LC), progression-free survival (PFS), and overall survival (OS).
resultsBetween March 2021 and March 2024, 10 patients (11 tumors) with a median age of 91 years (range: 83-96) were enrolled. Three patients received 36 Gy, three received 38 Gy, and four received 40 Gy. With a median follow-up of 27 months (range: 4-40), no dose-limiting adverse events were observed in any cohort, and thus the MTD was not reached. No acute adverse events were recorded. The only late adverse effect reported was one case (10%) of Grade 1 subcutaneous fibrosis at 6 months in the 36 Gy level. Cosmetic outcome was excellent or good in 100% of patients. At 24 months, local control, PFS and OS were 100%, 90% and 90%, respectively.
conclusionDefinitive SABR for primary breast cancer in elderly and/or frail patients is an exceptionally safe and well-tolerated procedure up to a dose of 40 Gy in 5 fractions. Furthermore, it demonstrates promising preliminary efficacy with excellent disease control. SABR stands as a highly effective, non-invasive alternative to surgery or exclusive hormone therapy in this selected patient cohort, strongly supporting further investigation for efficacy in phase II studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.